U.K was Silence Therapeutics’s largest region in fiscal 2023, bringing in $24.81M of $25.38M (98%).
| Geography | FY 2020 | FY 2022 | FY 2023 |
|---|---|---|---|
| U.K | $5.25M | $16.92M | $24.81M |
| Germany | $226.00K | $578.00K | $569.00K |
| Total | $5.48M | $17.50M | $25.38M |
Silence Therapeutics brought in $25.38M from its two regions in fiscal 2023, the year ended December 31, 2023. That was up 45.0% from $17.50M in fiscal 2022. U.K was the largest at $24.81M (97.8%), ahead of Germany at $569.00K (2.2%).
Compared with fiscal 2022, U.K grew 46.6% to $24.81M, while Germany fell 1.6% to $569.00K. From fiscal 2020 to 2023, combined revenue from these regions grew from $5.48M to $25.38M, a compound annual growth rate of 66.7%. U.K's share of the total rose from 95.9% to 97.8%.
Research Collaboration Income was Silence Therapeutics’s largest revenue line in fiscal 2023, bringing in $24.80M of $25.40M (98%).
| Products and services [axis] | FY 2022 | FY 2023 |
|---|---|---|
| Research Collaboration Income | $16.90M | $24.80M |
| Royalty Income | $600.00K | $600.00K |
| Total | $17.50M | $25.40M |
Silence Therapeutics brought in $25.40M from its two revenue lines in fiscal 2023, the year ended December 31, 2023. That was up 45.1% from $17.50M in fiscal 2022. Research Collaboration Income was the largest at $24.80M (97.6%), ahead of Royalty Income at $600.00K (2.4%).
Compared with fiscal 2022, Research Collaboration Income grew 46.7% to $24.80M and Royalty Income grew 0.0% to $600.00K.
Collaboration Agreement With Mallinckrodt was Silence Therapeutics’s largest revenue line in fiscal 2022, bringing in $11.70M of $17.60M (66%).
| Types of contracts [axis] | FY 2022 |
|---|---|
| Collaboration Agreement With Mallinckrodt | $11.70M |
| Astrazeneca Collaboration | $5.10M |
| Alnylam | $600.00K |
| Collaboration Agreement With Hansoh | $200.00K |
| Total | $17.60M |
Silence Therapeutics brought in $17.60M from its four revenue lines in fiscal 2022, the year ended December 31, 2022. Collaboration Agreement With Mallinckrodt was the largest at $11.70M (66.5%), ahead of Astrazeneca Collaboration at $5.10M (29.0%) and Alnylam at $600.00K (3.4%). The remaining revenue line, Collaboration Agreement With Hansoh, brought in $200.00K.
Silence Therapeutics (SLN) reports its revenue by geography, by products and services [axis] and by types of contracts [axis]. In fiscal 2023, U.K was its largest region, bringing in $24.81M (97.8% of the total), followed by Germany at $569.00K (2.2%).
U.K was Silence Therapeutics' largest region in fiscal 2023, bringing in $24.81M, or 97.8% of the $25.38M total across its two regions.
Research Collaboration Income was Silence Therapeutics' largest revenue line in fiscal 2023, bringing in $24.80M, or 97.6% of the $25.40M total across its two revenue lines.
U.K grew faster than Germany in fiscal 2023, up 46.6% from $16.92M to $24.81M. Germany fell 1.6% to $569.00K.
Every figure comes from Silence Therapeutics' annual financial filings, as reported. Each line keeps the name Silence Therapeutics gives it, and years follow its fiscal calendar.
Silence Therapeutics' revenue by geography goes back to fiscal 2020, with figures through fiscal 2023. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.